Cargando…

Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma

BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mairinger, Elena, Wessolly, Michael, Buderath, Paul, Borchert, Sabrina, Henrich, Larissa, Mach, Pawel, Steinborn, Julia, Kimming, Rainer, Jasani, Bharat, Schmid, Kurt Werner, Bankfalvi, Agnes, Mairinger, Fabian Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663300/
https://www.ncbi.nlm.nih.gov/pubmed/38023247
http://dx.doi.org/10.3389/fonc.2023.1252700
_version_ 1785138368997228544
author Mairinger, Elena
Wessolly, Michael
Buderath, Paul
Borchert, Sabrina
Henrich, Larissa
Mach, Pawel
Steinborn, Julia
Kimming, Rainer
Jasani, Bharat
Schmid, Kurt Werner
Bankfalvi, Agnes
Mairinger, Fabian Dominik
author_facet Mairinger, Elena
Wessolly, Michael
Buderath, Paul
Borchert, Sabrina
Henrich, Larissa
Mach, Pawel
Steinborn, Julia
Kimming, Rainer
Jasani, Bharat
Schmid, Kurt Werner
Bankfalvi, Agnes
Mairinger, Fabian Dominik
author_sort Mairinger, Elena
collection PubMed
description BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-binding proteins comprising various isoforms. MTs play a role in tumor development and drug resistance. Moreover, MTs influence inflammatory processes by regulating zinc homeostasis. In particular, T-cell function and polarization are particularly susceptible to changes in zinc status. The aim of the present study was to investigate a possible role of MT-mediated immune response and its association with prognostic outcome in ovarian cancer. METHODS: A retrospective study was conducted on a clinically well-characterized cohort of 24 patients with HGSOC treated at the University Hospital of Essen. Gene expression patterns for anti-cancer immunogenicity-related targets were performed using the NanoString nCounter platform for digital gene expression analysis with the appurtenant PanCancer Immune Profiling panel, consisting of 770 targets and 30 reference genes. Tumor-associated immunohistochemical MT protein expression was evaluated using a semi-quantitative four-tier Immunohistochemistry (IHC) scoring. RESULTS: MT immunoexpression was detected in 43% (10/23) of all HGSOC samples. MT immunoexpression levels showed a significant association to survival, leading to prolonged progression-free and overall survival in positively stained tumors. Furthermore, T-cell receptor signaling gene signature showed a strong activation in MT-positive tumors. Activated downstream signaling cascades resulting in elevated interferon-gamma expression with a shift in the balance between T helper cells (T(H)1 and T(H)2) could be observed in the MT-positive subgroup. In addition, a higher expression pattern of perforin and several granzymes could be detected, overall suggestive of acute, targeted anti-cancer immune response in MT-positive samples. CONCLUSION: This is the first study combining broad, digital mRNA screening of anti-tumor immune response–associated genes and their relation to MT-I/II in ovarian cancer. MT overexpression is associated with molecular characteristics of an anti-cancer immune response and is a strong prognostic marker in ovarian HGSOC. The observed immune cell activation associated with tumor MT expression comprises but is not limited to T cells and natural killer cells.
format Online
Article
Text
id pubmed-10663300
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106633002023-01-01 Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma Mairinger, Elena Wessolly, Michael Buderath, Paul Borchert, Sabrina Henrich, Larissa Mach, Pawel Steinborn, Julia Kimming, Rainer Jasani, Bharat Schmid, Kurt Werner Bankfalvi, Agnes Mairinger, Fabian Dominik Front Oncol Oncology BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-binding proteins comprising various isoforms. MTs play a role in tumor development and drug resistance. Moreover, MTs influence inflammatory processes by regulating zinc homeostasis. In particular, T-cell function and polarization are particularly susceptible to changes in zinc status. The aim of the present study was to investigate a possible role of MT-mediated immune response and its association with prognostic outcome in ovarian cancer. METHODS: A retrospective study was conducted on a clinically well-characterized cohort of 24 patients with HGSOC treated at the University Hospital of Essen. Gene expression patterns for anti-cancer immunogenicity-related targets were performed using the NanoString nCounter platform for digital gene expression analysis with the appurtenant PanCancer Immune Profiling panel, consisting of 770 targets and 30 reference genes. Tumor-associated immunohistochemical MT protein expression was evaluated using a semi-quantitative four-tier Immunohistochemistry (IHC) scoring. RESULTS: MT immunoexpression was detected in 43% (10/23) of all HGSOC samples. MT immunoexpression levels showed a significant association to survival, leading to prolonged progression-free and overall survival in positively stained tumors. Furthermore, T-cell receptor signaling gene signature showed a strong activation in MT-positive tumors. Activated downstream signaling cascades resulting in elevated interferon-gamma expression with a shift in the balance between T helper cells (T(H)1 and T(H)2) could be observed in the MT-positive subgroup. In addition, a higher expression pattern of perforin and several granzymes could be detected, overall suggestive of acute, targeted anti-cancer immune response in MT-positive samples. CONCLUSION: This is the first study combining broad, digital mRNA screening of anti-tumor immune response–associated genes and their relation to MT-I/II in ovarian cancer. MT overexpression is associated with molecular characteristics of an anti-cancer immune response and is a strong prognostic marker in ovarian HGSOC. The observed immune cell activation associated with tumor MT expression comprises but is not limited to T cells and natural killer cells. Frontiers Media S.A. 2023-11-08 /pmc/articles/PMC10663300/ /pubmed/38023247 http://dx.doi.org/10.3389/fonc.2023.1252700 Text en Copyright © 2023 Mairinger, Wessolly, Buderath, Borchert, Henrich, Mach, Steinborn, Kimming, Jasani, Schmid, Bankfalvi and Mairinger https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mairinger, Elena
Wessolly, Michael
Buderath, Paul
Borchert, Sabrina
Henrich, Larissa
Mach, Pawel
Steinborn, Julia
Kimming, Rainer
Jasani, Bharat
Schmid, Kurt Werner
Bankfalvi, Agnes
Mairinger, Fabian Dominik
Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title_full Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title_fullStr Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title_full_unstemmed Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title_short Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
title_sort tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663300/
https://www.ncbi.nlm.nih.gov/pubmed/38023247
http://dx.doi.org/10.3389/fonc.2023.1252700
work_keys_str_mv AT mairingerelena tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT wessollymichael tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT buderathpaul tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT borchertsabrina tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT henrichlarissa tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT machpawel tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT steinbornjulia tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT kimmingrainer tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT jasanibharat tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT schmidkurtwerner tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT bankfalviagnes tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma
AT mairingerfabiandominik tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma